Oric Pharmaceuticals Company Insiders
ORIC Stock | USD 7.03 0.48 6.39% |
Oric Pharmaceuticals' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Oric Pharmaceuticals suggests that all insiders are panicking. Oric Pharmaceuticals employs about 115 people. The company is managed by 12 executives with a total tenure of roughly 269 years, averaging almost 22.0 years of service per executive, having 9.58 employees per reported executive.
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
2024-12-16 | Pratik S Multani | Disposed 8850 @ 8.28 | View |
Monitoring Oric Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Oric |
Oric Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Oric Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Oric will maintain a workforce of about 120 employees by April 2025.Oric Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.3395) % which means that it has lost $0.3395 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5473) %, meaning that it created substantial loss on money invested by shareholders. Oric Pharmaceuticals' management efficiency ratios could be used to measure how well Oric Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of March 23, 2025, Return On Tangible Assets is expected to decline to -0.49. In addition to that, Return On Capital Employed is expected to decline to -0.6. At present, Oric Pharmaceuticals' Debt To Assets are projected to increase slightly based on the last few years of reporting.As of March 23, 2025, Common Stock Shares Outstanding is expected to decline to about 42.4 M. In addition to that, Net Loss is expected to decline to about (84.2 M)
Oric Pharmaceuticals Workforce Comparison
Oric Pharmaceuticals is regarded third in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 1,387. Oric Pharmaceuticals holds roughly 115 in number of employees claiming about 8% of equities under Health Care industry.
Oric Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oric Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oric Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Oric Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 6.5 | 13 | 2 | 1,396,166 | 48,166 |
2024-12-01 | 0.25 | 3 | 12 | 115,084 | 157,445 |
2024-06-01 | 6.0 | 6 | 1 | 148,500 | 20,500 |
2024-03-01 | 2.0 | 6 | 3 | 1,015,000 | 80,000 |
2023-12-01 | 0.2 | 2 | 10 | 52,709 | 105,896 |
2023-06-01 | 5.0 | 5 | 1 | 102,500 | 20,000 |
2022-12-01 | 0.3 | 3 | 10 | 28,748 | 49,281 |
2022-09-01 | 1.0 | 10 | 10 | 1,990,000 | 2,027,500 |
2021-12-01 | 2.0 | 6 | 3 | 511,083 | 1,504,327 |
2021-09-01 | 0.0909 | 1 | 11 | 33,250 | 23,634 |
2021-06-01 | 0.1389 | 5 | 36 | 83,125 | 58,350 |
2021-03-01 | 0.1071 | 3 | 28 | 460,000 | 1,106,292 |
2020-06-01 | 0.8421 | 32 | 38 | 19,196,560 | 24,718,600 |
Oric Pharmaceuticals Notable Stakeholders
An Oric Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Oric Pharmaceuticals often face trade-offs trying to please all of them. Oric Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Oric Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
BA MD | CoFounder Board | Profile | |
MD MBA | CEO President | Profile | |
CPA CPA | Chief Officer | Profile | |
BA BA | CoFounder Board | Profile | |
Lori Friedman | Chief Officer | Profile | |
Esq JD | G Counsel | Profile | |
MS MD | Chief Officer | Profile | |
Matthew Panuwat | Chief Officer | Profile | |
Richard Heyman | Independent CoFounder | Profile | |
Edna Maneval | Executive Development | Profile | |
Scott Lowe | CoFounder Board | Profile | |
Daniel Iazzetti | VP People | Profile |
About Oric Pharmaceuticals Management Performance
The success or failure of an entity such as Oric Pharmaceuticals often depends on how effective the management is. Oric Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Oric management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Oric management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.47) | (0.49) | |
Return On Capital Employed | (0.57) | (0.60) | |
Return On Assets | (0.47) | (0.49) | |
Return On Equity | (0.53) | (0.55) |
Please note, the presentation of Oric Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Oric Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Oric Pharmaceuticals' management manipulating its earnings.
Oric Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Oric Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Oric Pharmaceuticals within its industry.Oric Pharmaceuticals Manpower Efficiency
Return on Oric Pharmaceuticals Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.1M | |
Net Loss Per Executive | 10.7M | |
Working Capital Per Employee | 2.1M | |
Working Capital Per Executive | 19.8M |
Complementary Tools for Oric Stock analysis
When running Oric Pharmaceuticals' price analysis, check to measure Oric Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oric Pharmaceuticals is operating at the current time. Most of Oric Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oric Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oric Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oric Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |